Zimmer Biomet’s Acquisition Of Relign


Wilson Sonsini Goodrich & Rosati advised Relign on the deal.

Zimmer Biomet, a leading medical device manufacturer, announced in its earnings report that it has acquired Relign Corp., a privately held start-up in the growing $1.6 billion arthroscopy market and overall $5 billion sports medicine market. Relign’s offerings include the consolidation of three differentiated arthroscopy tower components into a single system, a first in the industry, and address a key portfolio gap for Zimmer Biomet in the sports medicine and broader ambulatory surgery center markets.

The Wilson team was led by Rob Ishii, Rich Mullen,(Picture) Erin Malone-Shkurkin, Elia Perez Villamarin, Elton Satusky, Alex Key, Miruna Predescu, Kexi Wang, Jim Heslin, David Hoffmeister, Eva Yin, Scott McCall, Michael Klippert, Myra Sutanto Shen, Matt Staples, Daniel Chen, Aren Balabanian, JeAnne Reyes, Jim McCann and Lee Cumberland.

Involved fees earner: Aren Balabanian – Wilson Sonsini Goodrich & Rosati; Daniel Chen – Wilson Sonsini Goodrich & Rosati; Lee Cumberland – Wilson Sonsini Goodrich & Rosati; James Heslin – Wilson Sonsini Goodrich & Rosati; David Hoffmeister – Wilson Sonsini Goodrich & Rosati; Robert Ishii – Wilson Sonsini Goodrich & Rosati; Alexander Key – Wilson Sonsini Goodrich & Rosati; Michael Klippert – Wilson Sonsini Goodrich & Rosati; Erin Malone-Shkurkin – Wilson Sonsini Goodrich & Rosati; Scott McCall – Wilson Sonsini Goodrich & Rosati; James McCann – Wilson Sonsini Goodrich & Rosati; Rich Mullen – Wilson Sonsini Goodrich & Rosati; Miruna Predescu – Wilson Sonsini Goodrich & Rosati; JeAnne Reyes – Wilson Sonsini Goodrich & Rosati; Elton Satusky – Wilson Sonsini Goodrich & Rosati; Matt Staples – Wilson Sonsini Goodrich & Rosati; Myra Sutanto Shen – Wilson Sonsini Goodrich & Rosati; Elia Villamarin – Wilson Sonsini Goodrich & Rosati; Eva Yin – Wilson Sonsini Goodrich & Rosati;

Law Firms: Wilson Sonsini Goodrich & Rosati;

Clients: RELIGN Corporation;

Author: Ambrogio Visconti